Preview

Siberian Journal of Clinical and Experimental Medicine

Advanced search

A multimarker approach to the diagnosis of heart failure with preserved ejection fraction

https://doi.org/10.29001/2073-8552-2025-40-4-61-70

Abstract

Background. Against the background of a steady increase in the incidence of heart failure with preserved ejection fraction (HFpEF), the highly laborious diagnosis of the disease hinders the timely implementation of therapeutic and preventive measures, which determines the relevance of our study.

Aim: To evaluate the significance of biomarkers, indices of myocardial strain and diastolic function in the diagnosis of HFpEF.

Material and Methods. According to a diastolic stress test (DST), 88 patients (65.9±5.4 years; 47.7% men) with left ventricular ejection fraction ≥50% were divided into 2 groups: 1 (n = 49) – with HFpEF, 2 (n = 39) – without HFpEF. All patients underwent echocardiography (ECHOCG) at rest and DST, evaluation of left atrial reservoir strain (LASr), left atrial stiffness index (LASI), diastolic function index E/e΄; biomarkers of immune inflammation; neurohumoral (NT-proBNP) and sympathoadrenal systems; fibrosis; growth factors; insulin resistance were studied: triglycerides/glucose (TyG) index; renal function; anemia, iron (Fe) status with assessment of percentage of transferrin iron saturation (%TIS); cortisol; progesterone (PGN). Factors associated with HFpEF were identified using simple or multivariate logistic regression, and 2 mathematical models of the disease were created. ROC analysis was used to identify cut-off points for indicators and HFpEF models were estimated.

Results. In group 1, women predominated (63.3 vs 38.5%; p = 0.021), mainly with functional class II according to the New York classification, with a higher body mass index (BMI) (32.4 ± 4.0 vs 29.9 ± 3.9 kg/m²; p = 0.003), the incidence of obesity (67.3 vs 43.6%; p = 0.025), iron deficiency (43.9 vs 34.6%; p = 0.033) and the use of β-blockers (73.5 vs 51.3%; p = 0.032). In multivariate analysis, HFpEF was associated with LASr: OR (95% CI) 0.722 (0.540–0.965) (p = 0.028) and E/e΄ at DST: OR (95% CI) 9.263 (1.912–44.885) (p = 0.006). Due to the unavailability of DST in practical healthcare, the following were included in 1 model without DST: gender, BMI > 30.4 kg/m², NT-proBNP > 360 pg/ml, LA volume index > 30 ml, E/e΄ > 9.8 at rest, LASr < 26%, TyG > 8.7 units, %TIS interaction < 27.7%, PGN < 1.7 nmol/l. The area under the ROC curve (AUC) was 0.879 (95% CI 0.806–0.951) and p < 0.001, specificity was 75.7%, sensitivity – 86.2% and the overall predictive value was 79.5%. Due to the secondary nature of the fibrotic process with the development of diastolic dysfunction, the following were included in model 2 without ECHOCG: gender, BMI > 30.4 kg/m², NT-proBNP >      360 pg/ml, cardiotrophin 1 > 587.0 pg/ml, TyG > 8.7 units, %TIS < 27.7%, PGN < 1.7 nmol/l. The AUC of the model was 0.830 (95% CI 0.734–0.927) and p < 0.001, specificity – 75.7%, sensitivity – 80.4%, overall predictive value – 78.3%.

Conclusion. Multimarker analysis revealed the diagnostic significance in HFpEF of a decrease in PGN level less than 1.7 nmol/l due to age-related hormonal remodeling, an increase in NT-proBNP level more than 360 pg/ml with neurohumoral activation, a decrease in transferrin iron saturation percentage less than 27.7% as a marker of iron deficiency, an increase in TyG insulin resistance index more than 8.7 units associated with obesity, LASr less than 26%, LASI more than 0.38 units, E/e΄ ratio more than 9.8 units at rest and more than 12.1 units during DST. Using a panel of laboratory markers including the previously mentioned levels of sST2, NT-proBNP, %LVAT, and hsTnT allows for a more precise assessment of the disease or its high risk of development, even without performing resting echocardiography or DST.

About the Authors

T. N. Enina
Tyumen Cardiology Research Center, Tomsk National Research Medical Center of the Russian Academy of Sciences (Tyumen Cardiology Research Center, Tomsk NRMC)
Россия

Tatiana N. Enina - Dr. Sci. (Med.), Leading Research Scientist, Department of Arterial Hypertension and Coronary Insufficiency, Clinical Cardiology of Tyumen Cardiology Research Center, Tomsk NRMC.

625026, Tyumen, Melnikaite St., 111



T. I. Petelina
Tyumen Cardiology Research Center, Tomsk National Research Medical Center of the Russian Academy of Sciences (Tyumen Cardiology Research Center, Tomsk NRMC)
Россия

Tatiana I. Petelina - Dr. Sci. (Med.), Head of Scientific and Clinical Laboratory, Tyumen Cardiology Research Center, Tomsk NRMC.

625026, Tyumen, Melnikaite St., 111



N. E. Shirokov
Tyumen Cardiology Research Center, Tomsk National Research Medical Center of the Russian Academy of Sciences (Tyumen Cardiology Research Center, Tomsk NRMC)
Россия

Nikita E. Shirokov - Cand. Sci. (Med.), Research Scientist, Laboratory of Instrumental Diagnostics, Tyumen Cardiology Research Center, Tomsk NRMC.

625026, Tyumen, Melnikaite St., 111



E. A. Gorbatenko
Tyumen Cardiology Research Center, Tomsk National Research Medical Center of the Russian Academy of Sciences (Tyumen Cardiology Research Center, Tomsk NRMC)
Россия

Elena A. Gorbatenko - Research Scientist, Laboratory of Instrumental Diagnostics, Tyumen Cardiology Research Center, Tomsk NRMC.

625026, Tyumen, Melnikaite St., 111



E. V. Sueva
Tyumen Cardiology Research Center, Tomsk National Research Medical Center of the Russian Academy of Sciences (Tyumen Cardiology Research Center, Tomsk NRMC)
Россия

Ekaterina V. Zueva - Research Scientist, Laboratory of Clinical Diagnostic and Molecular Genetic Studies, Scientific Department of Clinical Cardiology, Tyumen Cardiology Research Centre, Tomsk NRMC.

625026, Tyumen, Melnikaite St., 111



A. S. Davidchuk
Tyumen Cardiology Research Center, Tomsk National Research Medical Center of the Russian Academy of Sciences (Tyumen Cardiology Research Center, Tomsk NRMC)
Россия

Anastasia S. Davidchuk - Laboratory Research Assistant, Department of Arterial Hypertension and Coronary Insufficiency, Clinical Cardiology of Tyumen Cardiology Research Center, Tomsk NRMC.

625026, Tyumen, Melnikaite St., 111



L. I. Gapon
Tyumen Cardiology Research Center, Tomsk National Research Medical Center of the Russian Academy of Sciences (Tyumen Cardiology Research Center, Tomsk NRMC)
Россия

Liydmila I. Gapon - Dr. Sci. (Med.), Professor, Department of Arterial Hypertension and Coronary Insufficiency, Clinical Cardiology of Tyumen Cardiology Research Center, Tomsk NRMC.

625026, Tyumen, Melnikaite St., 111



References

1. Vasan R.S., Xanthakis V., Lyass A., Andersson C., Tsao C., Cheng S. et al. Epidemiology of left ventricular systolic dysfunction and heart failure in the Framingham Study: an echocardiographic study over 3 decades. JACC Cardiovasc. Imaging. 2018;11(1):1–11. https://doi.org/10.1016/j.jcmg.2017.08.007

2. Dzhioeva O.N., Timofeev Yu.S., Metelskaya V.A., Bogdanova A.A., Vedenikin T.Yu., Drapkina O.M. Role of epicardial adipose tissue in the pathogenesis of chronic inflammation in heart failure with preserved ejection fraction. Cardiovascular Therapy and Prevention. 2024;23(3):3928. (In Russ.). https://doi.org/10.15829/1728-8800-2024-3928. EDN: DGYKKN.

3. Wang T., Xu J., Zhang H., Tao L., Huang X. Triglyceride-glucose index for the detection of subclinical heart failure with preserved ejection fraction in patients with type 2 diabetes. Frontiers in Cardiovascular Medicine. 2023;10:1086978. https://doi.org/10.3389/fcvm.2023.1086978

4. Enina T.N., Shirokov N.E., Petelina T.I., Gorbatenko E.A., Kosterin M.D., Yaroslavskaya E.I. et al. Iron deficiency and diastolic function in heart failure with preserved ejection fraction. Siberian Journal of Clinical and Experimental Medicine. 2024;39(4):75–83. (In Russ.). https://doi.org/10.29001/2073-8552-2024-39-4-75-83

5. Chang J.W., Ramchandra R. The sympathetic nervous system in heart failure with preserved ejection fraction. Heart Fail. Rev. 2025;30(1):209–218. https://doi.org/10.1007/s10741-024-10456-0

6. Tong D., Schiattarella G.G., Jiang N., May H.I., Lavandero S., Gillette T.G. et al. Female sex is protective in a preclinical model of heart failure with preserved ejection fraction. Circulation. 2019;140(21):1769–1771. https://doi.org/10.1161/CIRCULATIONAHA.119.042267

7. Grekov E.A., Tyuzikov I.A., Smirnov A.V. Progesterone and prostate: a history of scientific study and the modern view of the problem. Andrologiya i genital’naya khirurgiya = Andrology and Genital Surgery. 2023;24(1):36–47. (In Russ.). https://doi.org/10.17650/2070-9781-2023-24-1-36-47

8. Vecchiola A., Uslar T., Friedrich I., Aguirre J., Sandoval A., Carvajal C.A. et al. The role of sex hormones in aldosterone biosynthesis and their potential impact on its mineralocorticoid receptor. Cardiovascular Endocrinology & Metabolism. 2024;13(3):e0305. https://doi.org/10.1097/XCE.0000000000000305

9. Shirokov N.E., Yaroslavskaya E.I., Kosterin M.D., Krinochkin D.V., Gorbatenko E.A., Enina T.N. et al. Left atrial stiffness index in the identification of heart failure with preserved ejection fraction. Cardiovascular Therapy and Prevention. 2024;23(4):3901. (In Russ.). https://doi.org/10.15829/1728-8800-2024-3901. EDN: LOWLXJ.

10. Shlyakhto E.V., Belenkov Yu.N., Boytsov S.A., Villevalde S.V., Galyavich A.S., Glezer M.G. et al. Interim analysis of a prospective observational multicenter registry study of patients with chronic heart failure in the Russian Federation “PRIORITETCHF”: initial characteristics and treatment of the first included patients. Russian Journal of Cardiology. 2023;28(10):5593. (In Russ.). https://doi.org/10.15829/1560-4071-2023-5593. EDN AMDHTV.

11. Ha Manh T., Do Anh D., Le Viet T. Effect of body mass index on N-terminal pro-brain natriuretic peptide values in patients with heart failure. The Egyptian Heart Journal. 2023;75(1):75. https://doi.org/10.1186/s43044023-00401-1

12. Azzo J.D., Dib M.J., Zagkos L., Zhao L., Wang Z., Chang C.P. et al. Proteomic associations of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) in heart failure with preserved ejection fraction. Circulation: Heart Failure. 2024;17(2):e011146. https://doi.org/10.1161/CIRCHEARTFAILURE.123.011146

13. Vitt K.N., Kuzheleva E.A., Tukish O.V., Soldatenko M.V., Kondratiev M.Yu., Ogurkova O.N. et al. Lowintensity inflammation as a manifestation of comorbidity and a factor in the unfavorable clinical course of heart failure with preserved ejection fraction. Cardiovascular Therapy and Prevention. 2024;23(2):3847. (In Russ.). https://doi.org/10.15829/1728-8800-2024-3847. EDN FEZEBR.

14. Seo M., Yamada T., Tamaki S., Watanabe T., Morita T., Furukawa Y. et al. Prognostic significance of cardiac 123I-MIBG SPECT imaging in heart failure patients with preserved ejection fraction. JACC Cardiovascular Imaging. 2022;15(4):655–668. https://doi.org/10.1016/j.jcmg.2021.08.003

15. Wu M., Ni D., Huang L.L., Qiu S. Association between the betablockers, calcium channel blockers, all-cause mortality and length of hospitalization in patients with heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials. Clinical Cardiology. 2023;46(8):845–852. https://doi.org/10.1002/clc.24058

16. Ravindran S., Rau C.D. The multifaceted role of mitochondria in cardiac function: insights and approaches. Cell Communication and Signaling. 2024;22(1):525. https://doi.org/10.1186/s12964-024-01899-x

17. Cao Y., Vergnes L., Wang Y.C., Panc C., Krishan K.C., Moore T.M. et al. Sex differences in heart mitochondria regulate diastolic dysfunction. Nature Communications. 2022;13:3850. https://doi.org/10.1038/s41467022-31544-5

18. Zhao D., Guallar E., Ballantyne C.M., Post W.S., Ouyang P., Vaidya D. et al. Sex hormones and incident heart failure in men and postmenopausal women: The atherosclerosis risk in communities study. The Journal of Clinical Endocrinology & Metabolism. 2020;105(10):e3798–3807. https://doi.org/10.1210/clinem/dgaa500

19. Tashfia A., Meha Q., Panicos A.K. Measuring stress: a review of the current cortisol and dehydroepiandrosterone (DHEA) measurement techniques and considerations for the future of mental health monitoring. Stress. 2023;26(1):29–42. https://doi.org/10.1080/10253890.2022.2164187

20. Cleland J.G.F. Defining iron deficiency in patients with heart failure. Nature Reviews Cardiology. 2024;21(1):1–2. https://doi.org/10.1038/s41569-023-00951-6


Review

For citations:


Enina T.N., Petelina T.I., Shirokov N.E., Gorbatenko E.A., Sueva E.V., Davidchuk A.S., Gapon L.I. A multimarker approach to the diagnosis of heart failure with preserved ejection fraction. Siberian Journal of Clinical and Experimental Medicine. 2025;40(4):61-70. (In Russ.) https://doi.org/10.29001/2073-8552-2025-40-4-61-70

Views: 79

JATS XML


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2713-2927 (Print)
ISSN 2713-265X (Online)